Finance

Beta
Lists
ROIV:NASDAQ
Roivant Sciences Ltd
$28.58
-3.22%
(-0.95) 1D
$28.58
0.00% (0.00)
After hours
Closed: Jun 5, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ROIV...
Open
$29.51
High
$29.64
Low
$28.56
Mkt. cap
20.56B
Avg. vol.
6.15M
Volume
4.64M
52-wk high
$32.79
52-wk low
$10.70
EPS
-$0.43
Beta
1.13
Shares outstanding
719.27M
No. of employees
721
Open
$29.51
High
$29.64
Low
$28.56
Mkt. cap
20.56B
Avg. vol.
6.15M
Volume
4.64M
52-wk high
$32.79
52-wk low
$10.70
EPS
-$0.43
Beta
1.13
Shares outstanding
719.27M
No. of employees
721
Analyst outlook
Analyst Ratings
Based on 9 analysts giving stock ratings to ROIV in the past 3 months
Strong Buy
Buy
8
Hold
1
Sell
0
12 month forecast
Based on 9 Wall Street analysts offering 12 month price targets for ROIV in the last 3 months.
Highest
Current $28.58
$42.00 (+46.96%)
Average
$36.53 (+27.82%)
Lowest
$29.29 (+2.48%)
News stories
From sources across the web
Profile
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
About Roivant Sciences Ltd
CEOMatt Gline
Employees721
FoundedApr 7, 2014
Headquarters-
SectorBiotechnology
Websiteroivant.com
Last report
May 20, 2026
Fiscal period
Q4 2026
EPS / Est. (USD)
-$0.32 / -$0.35
+9.31%beat
Revenue / Est. (USD)
2.52M / 3.91M
-35.60%miss
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
2.17M
1.57M
2.00M
2.52M
Cost of goods sold
152.57M
164.18M
166.08M
199.26M
Cost of revenue
152.57M
164.18M
166.08M
199.26M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
128.22M
129.52M
175.05M
173.07M
Operating expense
128.22M
129.52M
175.05M
173.07M
Total operating expenses
280.79M
293.70M
341.13M
372.33M
Operating income
-278.62M
-292.13M
-339.14M
-369.81M
Other non operating income
-13.54M
-26.65M
-16.07M
12.57M
EBT including unusual items
-269.26M
-159.04M
-290.37M
454.10M
EBT excluding unusual items
-243.84M
-273.44M
-311.94M
-316.06M
Income tax expense
4.65M
7.00M
23.33M
98.35M
Effective tax rate
-1.73%
-4.40%
-8.04%
21.66%
Other operating expenses
-
-
-
-
Net income
-223.36M
-113.52M
-265.89M
302.99M
Net profit margin
-10,292.86%
-7,225.91%
-13,301.20%
12,023.57%
Earnings per share
-0.25
-0.28
-0.24
-0.32
Interest and investment income
48.32M
45.34M
43.27M
41.18M
Interest expense
-
-
-
-
Net interest expenses
48.32M
45.34M
43.27M
41.18M
Depreciation and amortization charges
-
-
-
-
EBITDA
-277.52M
-291.21M
-338.44M
-369.17M
Gain or loss from assets sale
-
-
-
-11.03M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer